This study uses single-cell analysis of two severe COVID-19 patients before and after tocilizumab treatment to identify a monocyte subpopulation contributing to cytokine storms. Tocilizumab treatment effectively reduced inflammation while maintaining humoral and cellular antiviral immune responses. The study provides insights into tocilizumab's therapeutic effects and potential targets for treating cytokine storms in COVID-19.